May 2008
Volume 49, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2008
Intravitreal Triamcinolone Acetonide Inhibits Breakdown of the Blood-Retinal Barrier Through Differential Regulation of VEGF-A and Its Receptors in Early Diabetic Retinas
Author Affiliations & Notes
  • X. Zhang
    University of Sydney, Sydney, Australia
    Clinical Ophthalmology,
  • B. Bao
    Pathology, University of Sydney, Univeristy of Sydney, Australia
  • D. Lai
    University of Sydney, Sydney, Australia
    Bosch Institute,
  • R. Rapkins
    University of Sydney, Sydney, Australia
    Clinical Ophthalmology,
  • M. Gillies
    University of Sydney, Sydney, Australia
    Clinical Ophthalmology,
  • Footnotes
    Commercial Relationships  X. Zhang, None; B. Bao, None; D. Lai, None; R. Rapkins, None; M. Gillies, None.
  • Footnotes
    Support  None.
Investigative Ophthalmology & Visual Science May 2008, Vol.49, 3480. doi:https://doi.org/
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      X. Zhang, B. Bao, D. Lai, R. Rapkins, M. Gillies; Intravitreal Triamcinolone Acetonide Inhibits Breakdown of the Blood-Retinal Barrier Through Differential Regulation of VEGF-A and Its Receptors in Early Diabetic Retinas. Invest. Ophthalmol. Vis. Sci. 2008;49(13):3480. doi: https://doi.org/.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : To elucidate the mechanism of the unique beneficial effect of intravitreal steroid therapy on diabetic macular edema, we investigated the effect of locally administered triamcinolone acetonide (TA) on the expression of vascular endothelial growth factor(VEGF-A)and its receptors in streptozotocin (STZ) - induced diabetic rat retinas. We then correlated the expression of these proteins with breakdown of the blood-retinal barrier (BRB).

Methods: : 32 eyes of 16 diabetic and non-diabetic rats were divided into four groups. TA was injected into the vitreous of the right eye and saline was injected into the left eye (control) 3.5 weeks after induction of diabetes. Retinas were harvested 48h following treatment. mRNA and protein expression of VEGF-A, VEGF-A receptor 1 (FLT-1)andVEGF-A receptor 2 (FLK-1) were determined by real time RT-PCR and immunohistochemistry. BRB permeability was quantitated by measuring extravasated endogenous albumin and retinal thickness.

Results: : Diabetes induced retinal thickness and albumin extravasation were significantly reduced in TA-treated diabetic retinas to a level that was similar to sham-treated non-diabetic eyes. A close correlation between albumin leakage and increased expression of both Vegf-a and Flk-1 was noted in the diabetic retinas. TA down-regulated the expression of Vegf-a and Flk-1, but up-regulated the expression of Flt-1. TA did not alter the expression of these genes in non-diabetic retinas.

Conclusions: : Intravitreal injection of TA stabilizes the BRB in association with regulation of Vegf-a, Flk-1 and Flt-1 expression in early diabetic rat retinas.

Keywords: diabetic retinopathy • vascular endothelial growth factor • gene/expression 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×